Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAggressive LymphomasIndolent LymphomasTransplantationDiseaseChronic Lymphocytic Leukemia / Small Lymphocytic LymphomaMantle Cell LymphomaNHL, B-Cell Type, Diffuse Large CellNHL, B-Cell Type, Follicular Grade I-IIIaNHL, B-Cell Type, Follicular grade IIIbNHL, B-Cell Type, IndolentNHL, B-Cell Type, Lymphoplasmocytic / Waldenström's diseaseNHL, B-Cell Type, Marginal Zone LymphomaSubgroupCD20+unfitICD10C82.-C82.7C82.9C83.0C83.1C83.3C88.0-C91.1-MeSHLymphoma, Mantle-CellSequenceBORT1,3, Waldenström, C1 (PID2343) -|- C2 (PID2342) -|- C3,4 (PID2344) -|- C5 (PID2342).BORT1,6/RITU375, Waldenström, C1 (PID1235) -|- C2+3 (PID1266) -|- C4 (PID1235) -|- C5+6 (PID1266)CARF20/RITU375/DEXA20, Waldenström, C1 (PID2586) -|- C2-6 (PID2587) -|- C7-14 (PID2588)iNNOVATE: IBRU420/RITU375, Waldenström (PID1255) -|- IBRU420/RITU375, Maint. (PID1265)IXAC4/DEXA20, Waldenström, C1-2 (PID2025) -|- C3 (PID2026) -|- C4-8 (PID2027)IXAZ4/RITU1400/DEXA20, Waldenström (PID2025) -|- (PID2026) -|- (PID2027) -|- (PID310)VNTC(400/800), Waldenström, C1 (PID2003) -|- VNTC800, C2+ (PID2004)ChemotherapyChemo-substanceBendamustineBortezomibCarfilzomibCarmustineCyclophosphamideCytarabineDexamethasoneDoxorubicinEtoposideFludarabineIbrutinibIdelalisibIxazomibMelphalanPrednisoloneRituximabVenetoclaxVincristineZanubrutinibChemo-substanceBendamustineBortezomibCarfilzomibCarmustineCyclophosphamideCytarabineDexamethasoneDoxorubicinEtoposideFludarabineIbrutinibIdelalisibIxazomibMelphalanPrednisoloneRituximabVenetoclaxVincristineZanubrutinibChemo-substanceBendamustineBortezomibCarfilzomibCarmustineCyclophosphamideCytarabineDexamethasoneDoxorubicinEtoposideFludarabineIbrutinibIdelalisibIxazomibMelphalanPrednisoloneRituximabVenetoclaxVincristineZanubrutinibChemo-substanceBendamustineBortezomibCarfilzomibCarmustineCyclophosphamideCytarabineDexamethasoneDoxorubicinEtoposideFludarabineIbrutinibIdelalisibIxazomibMelphalanPrednisoloneRituximabVenetoclaxVincristineZanubrutinibNo. Substances123456 RadiotherapySupportive therapySupportive substanceAciclovirAllopurinolAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronMesnaParacetamolPegfilgrastimPrednisoloneSupportive substanceAciclovirAllopurinolAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronMesnaParacetamolPegfilgrastimPrednisoloneSupportive substanceAciclovirAllopurinolAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronMesnaParacetamolPegfilgrastimPrednisoloneSupportive substanceAciclovirAllopurinolAmphotericin BBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneDimetindenFilgrastimFosaprepitantGranisetronMesnaParacetamolPegfilgrastimPrednisoloneNo. Substances12345679Protocol classificationTherapy classificationalternativecurrent standardindividual (author)IntensityLow doseStandard doseTherapy indicationFirst lineRelapse therapySecond lineseveral possibleTherapy phaseInductionMaintenanceSalvageTherapy intentioncurativedisease controlpalliativeRisksAllergic ReactionAnemia Hb below 8g/dlAnemia Hb below 10g/dlArthalgiaAstheniaAtrial FibrillationBleedingCardiotoxicityConstipationDiarrheaDyspneaEdemaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)FatigueFebrile NeutropeniaHeadacheHematuriaHyperbilirubinemiaHyperglycemiaHypertensionHypotensionIncrease AminotransferasesIncrease in lipaseInfectionsInfusion ReactionLeukopeniaMyalgiasNauseaNeuropathyNeutropeniaPainPneumoniaPyrexiaRashThrombocytopenia below 50 000/µlUpper Respiratory Tract Infection only studiesPublicationAuthorBuske CCastillo JJDimopolous MDimopoulos MDimopoulos MAGavriatopoulou MGhobrial IMGopal AKHerold MKersten MKirschey SRobinson KSRummel MJSekiguchi NTam CSTedeschi ATreon SPTreon SP DiseaseFoll. L. °I-IIIa, kleines lymphozyt. L., Marginalzonenl., lymphoplasmoyt. L., Drittlinie bei Rituximab- u Alkylanz-RefraktäritätFoll. Lymphom Grad 1-2, MCL, lymphoplasmozytisches Lymphom, Therapieindikation, Erstlinie ECOG 0-2fortgeschrittener oder rezidivierter Morbus Waldenström, ECOG 0-2fortgeschrittenes follikuläres Lymphom, Mantelzelllymphom und Morbus Waldenström, Stadium III-IV, Erstlinie, ECOG 0-2MCL, follikuläres (Grad 1und 2), lymphoplasmozytisches, Marginalzonen-, kleines lymphozytisches Lymphom, Std. III u IV, ErstlinieMCL, follikuläres, lymphoplasmozytisches, kleines lymphozytisches u Marginalzonen-Lymphom, 2.-4.-LinieMorbus WaldenströmMorbus Waldenström, Alter über 65Morbus Waldenström, CD20+, ErstlinieMorbus Waldenström, Erstlinie oder Rezidivtherapie, ECOG: 0-2Morbus Waldenström, symptomatisch, Erst-oder ZweitlinieMorbus Waldenström, symptomatisch, ErstlinieMorbus Waldenström, Zweitlinie, rezidiv oder refraktär, ECOG 0-1Morbus Waldenström symptomatisch, Erstlinierezidivierte aggressive B-NHL, 18-65 Jahre, ECOG 0-2Waldenström´s Macroglobulinämie, MYD88 L265P pos., mindestens 1 Vortherapie, ECOG 0-2Waldenström´s Macroglobulinämie, MYD88 L265P pos., rezidiviert, therapierefraktär, oder ungeeignet für eine ChemotherapieWaldenström´s Macroglobulinämie, Zweitlinie, ECOG 0-2OriginBing Center for Waldenström´s Macrglobulinemia, Dana Faber-Institute, Boston, MA, USADana-Farber Cancer Institute, Boston, MADana-Farber Cancer Institute and Harvard Medical School, Boston, USADepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, iNNOVATE StudyDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, iNNOVATE trialDepartment of Clinical Therapeutics, University of Athens School of Medicine, Athens, GreeceDepartment of Haematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg University MainzDepartment of Hematology, University of Amsterdam, HOVON124/ ECWM-R2 StudyDepartment of Internal Medicine III, University ofMunich, German Low-Grade Lymphoma Study GroupDepartment of Medicine, Division of Medical Oncology, University of Washington School of Medicine, USADepartments of Clinical Therapeutics, Internal Medicine, and the Second Department of Propedeutic Medicine, University of Athens School of MedicineDivision of Hematology, Ospedale Niguarda Ca´Granda, Milano, ItalyHelios Klinikum, Hämatologie/Onkologie, Erfurt, Deutschland, Studie OSHO# 19Hematology Division, National Hospital Organization Disaster Medical Center, Tachikawa, TokyoNational and Kapodistrian University of Athens, Athens, GreecePeter MacCallum Cancer Centre, Melbourne, VIC, Australia, BGB-3111-302 (ASPEN trial)QE II Helath Sciences Centre, Halifax, Nova Scotia, CanadaStudy Group indolent Lymphomas (StiL)Protocols in Revision 28 protocols foundProtocols under revision.Bortezomib 1,3, Waldenström's disease, cycle 1 (PID2343 V1.0)Bortezomib 1.6 / Rituximab 375 - Bortezomib 1.6 Waldenström's disease, cycle 2+3+5+6 (PID1266 V1.0)Bortezomib 1.6 / Rituximab 375 / Dexamethasone 40, Waldenström's disease, cycle 2,5 (PID2342 V1.0)Bortezomib 1.6 / Rituximab 375, Waldenström's disease, cycle 1+4 (PID1235 V1.0)Bortezomib 1.6, Waldenström's disease, cycle 3-4 (PID2344 V1.0)Carfilzomib 20 / Rituximab 375 / Dexamethasone 20, Waldenström, cycle 1 (PID2586 V1.0)Carfilzomib 36 / Rituximab 375 / Dexamethasone 20, Waldenström, cycle 2-6 (PID2587 V1.0)Carfilzomib 36 / Rituximab 375 / Dexamethasone 20, Waldenström, cycle 7-14 (PID2588 V1.0)Dexamethasone 20 / Rituximab 375 / Cyclophosphamide 100, Waldenström's disease (PID52 V1.1)Ibrutinib 420 / Rituximab 375, Waldenström's disease (PID1255 V1.0)Ibrutinib 420 / Rituximab 375, Waldenström's disease, maintenance (PID1265 V1.0)Ibrutinib 420, Waldenström's disease (PID585 V1.1)Idelalisib 150, indolent B-non-Hodgkin Lymphoma (PID308 V1.2)Ixazomib 4 / Dexamethasone 20, Waldenström's disease, cycle 1-2 (PID2025 V1.0)Ixazomib 4 / Rituximab 1400 / Dexamethasone 20, Waldenström's disease, cycle 4-8 (PID2027 V1.0)Ixazomib 4 / Rituximab 375 / Dexamethasone 20, Waldenström's disease, cycle 3 (PID2026 V1.0)R-BOP - Rituximab 375 / Bendamustine 60 / Vincristine 2 / Prednisolone 100, indolent B non-Hodgkin Lymphoma and Mantle Cell Lymphoma (PID297 V1.0)R-CHOP - Rituximab 375 / Cyclophosphamide 750 / Doxorubicin 50 / Vincristine 2 / Prednisolone, 100 Waldenström's disease (PID676 V1.0)R-COP - Rituximab 375 / Cyclophosphamide 400 / Vincristine 2 / Prednisolone 100, indolent B non-Hodgkin Lymphoma and Mantle Cell Lymphoma (PID298 V1.0)R-DexaBEAM - Rituximab 375 / Dexamethasone 8 / Carmustine 60 / Etoposide 75 / Cytarabine 100 / Melphalan 20, B-Non-Hodgkin Lymphoma (PID1006 V1.0)R-FC - Rituximab 375 / Fludarabine 25 / Cyclophosphamide 250, Waldenström's disease (PID674 V1.1)R-miniCHOP - Rituximab 375 / Cyclophosphamide 375 / Doxorubicin 25 / Vincristine 0.7 / Prednisolone 60, Waldenström's disease (PID673 V1.0)Rituximab 375 / Bendamustine 90, indolent B-non-Hodgkin Lymphoma and Mantle Cell Lymphoma, first-line (PID271 V1.0)Rituximab 375 / Bendamustine 90, indolent B-non-Hodgkin Lymphoma and Mantle Cell Lymphoma, second line (PID270 V1.0)Rituximab 375, Waldenström's disease (PID677 V1.0)Venetoclax (400/800), Waldenström's disease, cycle 1 (PID2003 V1.0)Venetoclax 800, Waldenström's disease, cycle 2+ (PID2004 V1.0)Zanubrutinib 160, Waldenström's disease (PID1918 V1.0)
